Please wait a minute...
European Journal of Gynaecological Oncology  2020, Vol. 41 Issue (3): 339-342    DOI: 10.31083/j.ejgo.2020.03.5181
Systematic Review Previous articles | Next articles
Prognostic value of Foxp3+ regulatory T cells in endometrial cancer: a meta-analysis
B.-H. Zhang1, L. Li1, J. Ji1, J. Guo1, X.-L. Zhou1, H. Xu1, F. Cao1, X.-H. Tong2()
1Department of Obstetrics and Gynecology, Punan Hospital of Pudong New District of Shanghai, Shanghai, China
2Department of Obstetrics and Gynecology, Shanghai Changning Maternity & Infant Health Hospital, Shanghai, China
Download:  PDF(1138KB)  ( 289 ) Full text   ( 12 )
Export:  BibTeX | EndNote (RIS)      
Abstract  

Endometrial cancer is the second most common gynecologic cancer globally, and the prognosis of advanced or recurrent endometrial cancer is very poor. Currently, the prognostic value of Forkhead box protein P3 (FoxP3)+ regulatory T cells (Tregs) in endometrial cancer is unclear. This meta-analysis aimed to evaluate prognostic significance of Foxp3+ Tregs in endometrial cancer. The authors searched the literature from databases including PubMed, Cocohrane, and Web of Science, and selected four eligible studies for further analysis. Meta-analysis of the survival data from 869 endometrial cancer patients showed that there were no significant differences in overall survival, disease-free survival, relapse-free survival or disease-specific survival between patients with high levels of Foxp3+ Tregs infiltration, and those with low levels of Foxp3+ Tregs. In summary, this meta-analysis provided systemic evidence that Foxp3+ Tregs infiltration is not significantly associated with the prognosis of patients with endometrial cancer.

Key words:  Foxp3      Tregs      Endometrial cancer      Prognosis      Meta-analysis     
Submitted:  22 January 2019      Accepted:  25 February 2019      Published:  15 June 2019     
Fund: PWRl 2018-10/Shanghai Pudong new area health and family planning commission leading personnel training project
*Corresponding Author(s):  X.-H. Tong     E-mail:  zbh513@sina.com

Cite this article: 

B.-H. Zhang, L. Li, J. Ji, J. Guo, X.-L. Zhou, H. Xu, F. Cao, X.-H. Tong. Prognostic value of Foxp3+ regulatory T cells in endometrial cancer: a meta-analysis. European Journal of Gynaecological Oncology, 2020, 41(3): 339-342.

URL: 

https://ejgo.imrpress.com/EN/10.31083/j.ejgo.2020.03.5181     OR     https://ejgo.imrpress.com/EN/Y2020/V41/I3/339

Figure 1.  — Flow diagram of the procedure of literature search.

Table 1  Main features and methodological assessment of the included studies
Study Year Patients source No. of patients NOS score Methods Outcome Follow-up (month)
Kubler [14] 2014 Germany 163 9 IHC RFS 216
Workel [13] 2016 Netherland 305 9 IHC DFS/DSS 240
Giatromanolaki [16] 2008 Greece 91 9 IHC OS 200
De Jong [15] 2009 Netherland 310 9 IHC DFS 64
Figure 2.  — No significant association of Foxp3+ Tregs with OS of patients with endometrial cancer.

Figure 3.  — No significant association of Foxp3+ Tregs with RFS of patients with endometrial cancer.

Figure 4.  — No significant association of Foxp3+ Tregs with DFS of patients with endometrial cancer.

Figure 5.  — No significant association of Foxp3+ Tregs with DSS of patients with endometrial cancer.

[1] Siegel R.L., Miller K.D., Jemal A.: “Cancer statistics, 2015”. CA Cancer J. Clin., 2017, 65, 5.
doi: 10.3322/caac.21254 pmid: 25559415
[2] Erdemoglu E., Yalcin Y., Bozkurt K.K., Erdemoglu E.: “Surgical staging of low-risk Stage IA endometrioid endometrial cancers”. Eur. J. Gynaecol. Oncol., 2017, 38, 80.
pmid: 29767870
[3] Kölbl A.C., Schlenk K., Behrendt N., Andergassen U.: “The importance of hCG in human endometrial adenocarcinoma and breast cancer”. Int. J. Biol. Markers, 2018, 33, 33.
doi: 10.5301/ijbm.5000290 pmid: 28967068
[4] Roli L., Pecoraro V., Trenti T.: “Can NGAL be employed as prognostic and diagnostic biomarker in human cancers? A systematic review of current evidence”. Int. J. Biol. Markers, 2017, 32, e53.
doi: 10.5301/jbm.5000245 pmid: 28106227
[5] Liotta L.A., Kohn E.C.: “The microenvironment of the tumour-host interface”. Nature, 2001, 411, 375.
doi: 10.1038/35077241 pmid: 11357145
[6] Grivennikov S.I., Greten F.R., Karin M.: “Immunity, inflammation, and cancer”. Cell, 2010, 140, 883.
doi: 10.1016/j.cell.2010.01.025 pmid: 20303878
[7] Li H., Fan X., Houghton J.: “Tumor microenvironment: the role of the tumor stroma in cancer”. J. Cell. Biochem., 2007, 101, 805.
doi: 10.1002/jcb.21159 pmid: 17226777
[8] Najafi M., Farhood B., Mortezaee K.: “Contribution of regulatory T cells to cancer: A review”. J. Cell. Physiol., 2019, 234, 7983.
doi: 10.1002/jcp.27553 pmid: 30317612
[9] DeLeeuw R.J., Kost S.E., Kakal J.A., Nelson B.H.: “The prognostic value of FoxP3+ tumor-infiltrating lymphocytes in cancer: a critical review of the literature”. Clin. Cancer Res., 2012, 18, 3022.
doi: 10.1158/1078-0432.CCR-11-3216 pmid: 22510350
[10] Ibrahim E.M., Al Foheidi M.E., Al Mansour M.M., Kazkaz G.A.: “The prognostic value of tumor-infiltrating lymphocytes in triplenegative breast cancer: a meta-analysis”. Breast Cancer Res. Treat., 2014, 148, 467.
doi: 10.1007/s10549-014-3185-2 pmid: 25361613
[11] Yeong J., Thike A.A., Lim J.C., Lee B., Li H., Wong S.C., et al.: “Higher densities of Foxp3+ regulatory T cells are associated with better prognosis in triple-negative breast cancer”. Breast Cancer Res. Treat., 2017, 163, 21.
doi: 10.1007/s10549-017-4161-4 pmid: 28233108
[12] Stang A.: “Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses”. Eur. J. Epidemiol., 2010, 25, 603.
doi: 10.1007/s10654-010-9491-z pmid: 20652370
[13] Workel H.H., Komdeur F.L., Wouters M.C., Plat A., Klip H.G., Eggink F.A., et al.: “CD103 defines intraepithelial CD8+ PD1+ tumour-infiltrating lymphocytes of prognostic significance in endometrial adenocarcinoma”. Eur. J. Cancer, 2016, 60, 1.
doi: 10.1016/j.ejca.2016.02.026 pmid: 27038842
[14] Kübler K., Ayub T.H., Weber S.K., Zivanovic O., Abramian A., Keyver Paik M.D., et al.: “Prognostic significance of tumor-associated macrophages in endometrial adenocarcinoma”. Gynecol. Oncol., 2014, 135, 176.
doi: 10.1016/j.ygyno.2014.08.028
[15] de Jong R.A., Leffers N., Boezen H.M., ten Hoor K.A., van der Zee A.G., Hollema H., Nijman H.W.: “Presence of tumor-infiltrating lymphocytes is an independent prognostic factor in type I and II endometrial cancer”. Gynecol. Oncol., 2009, 114, 105.
doi: 10.1016/j.ygyno.2009.03.022 pmid: 19411095
[16] Giatromanolaki A., Bates G.J., Koukourakis M.I., Sivridis E., Gatter K.C., Harris A.L., Banham A.H.: “The presence of tumor-infiltrating FOXP3+ lymphocytes correlates with intratumoral angiogenesis in endometrial cancer”. Gynecol. Oncol., 2008, 110, 216.
doi: 10.1016/j.ygyno.2008.04.021 pmid: 18533240
[17] Kosmaczewska A., Ciszak L., Potoczek S., Frydecka I.: “The significance of Treg cells in defective tumor immunity”. Arch. Immunol. Ther. Exp. (Warsz.), 2008, 56, 181.
doi: 10.1007/s00005-008-0018-1
[18] Tanaka A., Sakaguchi S.: “Regulatory T cells in cancer immunotherapy”. Cell Res., 2017, 27, 109.
doi: 10.1038/cr.2016.151 pmid: 27995907
[19] Que Y., Xiao W., Guan Y.X., Liang Y., Yan S.M., Chen H.Y., et al.: “PD-L1 Expression Is Associated with FOXP3+ Regulatory T-Cell Infiltration of Soft Tissue Sarcoma and Poor Patient Prognosis”. J. Cancer, 2017, 8, 2018.
doi: 10.7150/jca.18683 pmid: 28819402
[20] Shen Z., Zhou S., Wang Y., Li R.L., Zhong C., Liang C., Sun Y.: “Higher intratumoral infiltrated Foxp3+ Treg numbers and Foxp3+/CD8+ ratio are associated with adverse prognosis in resectable gastric cancer”. J. Cancer Res. Clin. Oncol., 2010, 136, 1585.
doi: 10.1007/s00432-010-0816-9 pmid: 20221835
[21] DeLeeuw R.J., Kost S.E., Kakal J.A., Nelson B.H.: “The prognostic value of FoxP3+ tumor-infiltrating lymphocytes in cancer: a critical review of the literature”. Clin. Cancer Res., 2012, 18, 3022.
doi: 10.1158/1078-0432.CCR-11-3216 pmid: 22510350
[22] Rashid T., Young Pierce J.L., Garrett Mayer E., Graybill W., Neal S., Spruill L.S.: “CD8, FoxP3, and CD45RO+ Lymphocytic Infiltrates in Type I and Type II Endometrial Cancers in African American and European American Females”. Int. J. Gynecol. Pathol. 2017, 36, 540.
doi: 10.1097/PGP.0000000000000359 pmid: 28114190
[1] Ikuji Shimazaki, Yasunori Hashiguchi, Makoto Yamauchi, Mari Kasai, Takeshi Fukuda, Tomoyuki Ichimura, Tomoyo Yasui, Toshiyuki Sumi. Secondary small cell vaginal cancer after operative therapy for endometrial cancer[J]. European Journal of Gynaecological Oncology, 2020, 41(5): 821-823.
[2] Yu Hui Lim, Sheow Lei Lim, Linda Xiao Hui Lin, Lay Tin Soh, Hoon Seng Khoo Tan, Richard Ming Chert Yeo, Timothy Yong Kuei Lim. Sequential Chemoradiation versus Radiation for the Adjuvant Treatment of Stage III Endometrioid Adenocarcinoma of the Uterus[J]. European Journal of Gynaecological Oncology, 2020, 41(5): 705-712.
[3] Eda Kucuktulu, Ahmet Fatih Yurekli. Simultaneous Integrated Intensity Modulated Radiotherapy Boost for Gynecological Cancer when Brachytherapy is not an Option[J]. European Journal of Gynaecological Oncology, 2020, 41(5): 720-725.
[4] Wook Youn Kim, Shin Hee Seo, Seung-Hyuk Shim, Jin Hee Park, Hyung Kyu Park, Kyeong A So, Tae Jin Kim, Sun Joo Lee. Correlation of immunohistochemistry and silver in situ hybridization for the assessment of c-MET in uterine cervical cancer patients treated with radical hysterectomy[J]. European Journal of Gynaecological Oncology, 2020, 41(5): 745-752.
[5] Michelle F. Benoit, Kristy K. Ward. Uterine Cancer Normogram to Predict Lymph Node Metastasis: Comparison to the Mayo Algorithm and an External Validation of a Model in a North American Population[J]. European Journal of Gynaecological Oncology, 2020, 41(5): 681-684.
[6] Yi-fan Luo, Li-xiang Ren, Ming-yan Jiang, Yang Chu. A systematic review and meta-analysis on the effects of metformin on survival outcomes and risk in women with cervical cancer[J]. European Journal of Gynaecological Oncology, 2020, 41(4): 504-507.
[7] Liman Yang, Jing Jin, Juhong Liu. Correlation of MMP2-C1306T (rs243865) and MMP7-181A/G (rs11568818) with cervical cancer: a meta-analysis[J]. European Journal of Gynaecological Oncology, 2020, 41(4): 508-512.
[8] Chados Nikolaos, Gregoriou Odysseas, Salakos Nicolaos, Kondis Agatha, Deligeoroglou Efthymios. The prognostic significance and immuno-expression of survivin, mutant p53 and bcl-2 in 92 cases of epithelial ovarian cancer[J]. European Journal of Gynaecological Oncology, 2020, 41(4): 517-522.
[9] Yusuf Cakmak, Tufan Oge. The effect of age on prediction of concurrent endometrial cancer in patients with atypical endometrial hyperplasia[J]. European Journal of Gynaecological Oncology, 2020, 41(4): 531-535.
[10] Sun Yi Choe, Jung-Woo Park. Prognostic significance of the number of metastatic lymph nodes in early cervical cancer: a retrospective study[J]. European Journal of Gynaecological Oncology, 2020, 41(4): 536-540.
[11] Di Wu, Jirui Zhang, Chengxi Yang. Effect of letrozole combined with testosterone on the proliferation and apoptosis of endometrial carcinoma cells[J]. European Journal of Gynaecological Oncology, 2020, 41(4): 604-608.
[12] Chen J.Y., Wang Z.Q., Liang S.C., Hou H.Y., Chen D.B., Wang J.L.. Sentinel lymph node mapping with carbon nanoparticles in endometrial cancer[J]. European Journal of Gynaecological Oncology, 2020, 41(3): 408-414.
[13] J. Feng, J. Wu, M. Zhang, J. Wang, K. Chen, X. Li, J. Xie, J. Zhang, C. Wang. Oleic acid promotes the development of endometrial cancer by up-regulating KLF4 expression[J]. European Journal of Gynaecological Oncology, 2020, 41(3): 432-438.
[14] Jingyuan Wang, Xiaoping Li, Danhua Shen, Xiao Wang, Zhiqi Wang, Jianliu Wang. Clear-cell carcinoma of the endometrium:type I or type II endometrial carcinoma?[J]. European Journal of Gynaecological Oncology, 2020, 41(3): 449-454.
[15] S. Liu, F. Ruan, M. Shi, Y. Liu, W. Li, B. Bi, H. Wang, W. Lv. Safe fertility-preserving management in a young woman with endometrial cancer[J]. European Journal of Gynaecological Oncology, 2020, 41(3): 476-479.
No Suggested Reading articles found!